Synta Phara (SNTA) Recieves Favorable Feedback Regarding Phase 2 - Jefferies

Article Stock Quotes (1) Comments (0)

Analyst Jefferies today reiterated a Buy rating on Synta Pharmaceuticals Corp. (Nasdaq: SNTA). They continue to see upside to shares on strong GALAXY Data. Recent feedback was generally favorable regarding interpretation of Phase 2 data

“We remain positive on SNTA and see the upcoming second interim GALAXY analysis as a near term catalyst for shares,” said analyst Thomas Wei.

The drug has high awareness and favorable impressions among long cancer doctors, and feedback from enrollment outside the U.S. is unlikely to impair results, noted a recent report.

Jefferies has a $15 price target on Synta Pharmaceuticals.

For an analyst ratings summary and ratings history on Synta Pharma. click here. For more ratings news on Synta Pharma. click here.

Shares of Synta Pharma. closed at $8.03 yesterday, with a 52 week range of $3.02-$8.50.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
• Actavis (ACT) Fairly Valued After Run-Up - Jefferies
• Deutsche Bank Starts Taylor Morrison Home (TMHC) at Hold, Says 'Risks Downplayed'

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?